⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
If you are taking semaglutide (Ozempic, Rybelsus) or tirzepatide (Mounjaro) for type 2 diabetes or obesity, two numbers matter more than any others for tracking your health progress: HbA1c and, if you use a continuous glucose monitor (CGM), Time-in-Range (TIR). Both are blood sugar metrics — but they measure different things, and both are interpreted differently for Indian patients than for Western populations.
Consult your healthcare provider before starting any medication. All blood test interpretation should be done with your treating physician.
This guide explains what HbA1c actually measures, why the standard "normal" ranges may not apply to Indians, what Time-in-Range means and how to use it if you have a Freestyle Libre or Dexcom, and what to expect from these numbers as your GLP-1 therapy progresses.
HbA1c (glycated haemoglobin, also written as HbA1c, A1C, or glycosylated haemoglobin) measures the percentage of haemoglobin — the oxygen-carrying protein in your red blood cells — that has glucose attached to it.
Since red blood cells live for approximately 90–120 days, HbA1c reflects your average blood glucose level over the past 2–3 months. A single blood glucose reading tells you what your sugar is right now; HbA1c tells you what it has been on average for the past quarter.
How it is measured: A simple blood test, available at any diagnostic laboratory in India. Results typically available within 24 hours.
Major Indian lab chains: SRL Diagnostics, Thyrocare (₹150–₹250), Dr. Lal PathLabs, Metropolis Healthcare.
| HbA1c Value | Interpretation |
|---|---|
| Below 5.7% | Normal (non-diabetic) |
| 5.7% – 6.4% | Prediabetes |
| 6.5% and above | Diabetes diagnosis threshold |
| Below 7.0% | Target for most people with T2DM on treatment |
| Below 8.0% | Acceptable target for elderly patients or those with hypoglycaemia risk |
This is critically important and poorly understood by many patients in India. South Asian populations have higher HbA1c values at equivalent blood glucose levels compared to Europeans. Multiple studies published in journals including Diabetologia and the British Medical Journal have confirmed this:
Additionally, India-specific factors affect HbA1c accuracy:
The Research Society for Study of Diabetes in India (RSSDI) and Endocrine Society of India (ESI) guidelines recommend:
| Patient Type | HbA1c Target |
|---|---|
| Most adults with T2DM | Below 7.0% |
| Young patients, newly diagnosed, no hypoglycaemia risk | Below 6.5% |
| Elderly patients (65+), significant comorbidities | Below 7.5%–8.0% |
| Pregnant women with pre-existing T2DM | Below 6.5% |
| Patients with frequent hypoglycaemia | Below 8.0% |
Important: GLP-1 medications are among the most effective agents for reducing HbA1c. Clinical trial data:
Understanding the timeline prevents premature disappointment:
| Time on GLP-1 | Expected HbA1c Change |
|---|---|
| 3 months (first test) | 0.5–1.0% reduction (on titration doses) |
| 6 months | 1.0–2.0% reduction (at or near therapeutic dose) |
| 12 months | Maximum effect — 1.5–2.3% total reduction typical |
| Ongoing | Sustained reduction as long as therapy continues |
What to tell your doctor at your 3-month appointment: Ask specifically whether to check HbA1c at the 3-month mark or wait until 6 months. Many endocrinologists prefer the 6-month check as the first meaningful assessment, because the first 3 months involve dose titration rather than therapeutic dosing.
HbA1c is an average — and averages can be misleading. Consider two patients with an identical HbA1c of 7.0%:
Both have the same HbA1c, but Patient B is experiencing dangerous glucose variability that HbA1c cannot capture. This is where Time-in-Range (TIR) comes in.
Time-in-Range is the percentage of time each day that your blood glucose stays within a target range. It can only be measured with a Continuous Glucose Monitor (CGM) — a sensor worn on your arm or abdomen that reads glucose every 5–15 minutes.
CGMs available in India (2024–2025):
| Target Range | Glucose (mg/dL) | Target TIR |
|---|---|---|
| Time In Range | 70–180 mg/dL | Above 70% of the day |
| Time Below Range | Below 70 mg/dL | Below 4% of the day |
| Time Above Range | Above 180 mg/dL | Below 25% of the day |
Indian-specific note: The international TIR range of 70–180 mg/dL is based on predominantly Western populations. Some Indian diabetes specialists prefer a tighter target of 80–160 mg/dL, given higher metabolic risk in South Asians at lower glucose levels. Discuss your personal target with your endocrinologist.
GLP-1 medications improve both HbA1c and TIR through complementary mechanisms:
In clinical studies, GLP-1 medications typically increase TIR by 10–20 percentage points — a clinically meaningful improvement.
| Phase | When to Test |
|---|---|
| Before starting | Baseline (essential) |
| First 6 months | Every 3 months |
| Once stable on maintenance dose | Every 6 months |
| If HbA1c is above target | Every 3 months until controlled |
Where to test affordably:
For most GLP-1 users in India:
Cost note: At ₹2,000–₹2,500 for a 14-day FreeStyle Libre sensor, continuous monitoring costs ₹4,000–₹5,000/month — meaningful for many Indian patients. A quarterly 2-week wear strategy costs approximately ₹8,000–₹10,000/year, which is more sustainable.
Q: My HbA1c went down from 9.2% to 7.8% in 6 months. Is that good progress?
A: Yes, a 1.4 percentage point reduction in 6 months is excellent. You are on the right trajectory. Continue the current dose and approach. Many patients see further reduction at 12 months as the medication's full effect develops.
Q: My HbA1c is 6.3% but my fasting glucose is always 115–125 mg/dL. My doctor says this is prediabetes. Why is the HbA1c normal?
A: This discordance is common in India. Possibilities include: iron deficiency anaemia falsely lowering your HbA1c, a haemoglobin variant affecting results, or simply normal variation between measures. Ask your doctor to check fasting plasma glucose and a 2-hour oral glucose tolerance test alongside HbA1c to get a complete picture.
Q: I have been on Ozempic for 4 months and my HbA1c only dropped 0.4%. Is it not working?
A: At 4 months, you are likely still on a low titration dose (0.5 mg or early 1 mg). The full HbA1c effect develops at the therapeutic dose over 6–12 months. Do not judge efficacy until you have been at your target dose for at least 3 months. Also ensure you are not inadvertently adding back calories through frequent snacking — GLP-1 reduces appetite but cannot compensate for significant caloric surplus.
Q: Can I use a glucometer instead of a CGM to track Time-in-Range?
A: Not accurately. A standard glucometer gives point-in-time measurements — typically before meals and 2 hours after. CGMs provide continuous data every 5–15 minutes. You can approximate TIR by testing more frequently (8–10 times daily), but this is burdensome and misses overnight and post-snack spikes.
| Mistake | Why It Matters |
|---|---|
| Testing HbA1c every month | Red blood cells live 3 months; monthly testing is meaningless |
| Comparing your HbA1c to Western reference ranges without adjustment | May underestimate risk in Indian patients |
| Not correcting for anaemia before interpreting HbA1c | Iron deficiency artificially raises HbA1c |
| Assuming HbA1c improvement means TIR is also good | Average can hide dangerous glucose swings |
| Not telling your lab you have a haemoglobin variant | Can make HbA1c result unreliable |
| Panicking at a single high HbA1c reading without context | One reading is a point of data, not a verdict |
| Metric | What It Measures | How Often to Test | Target on GLP-1 |
|---|---|---|---|
| HbA1c | 3-month average glucose | Every 3–6 months | Below 7.0% (most T2DM patients) |
| Fasting glucose | Overnight fasting glucose | Weekly self-monitoring recommended | 80–130 mg/dL |
| Post-meal glucose (2hr) | Glucose rise after food | Periodically with glucometer | Below 180 mg/dL |
| Time-in-Range | % of time within target glucose band | Via CGM, wear 2 weeks quarterly | Above 70% in 70–180 mg/dL range |
Understanding HbA1c and Time-in-Range transforms you from a passive medication recipient to an active participant in your own metabolic health. On GLP-1 therapy, these numbers should be moving in the right direction — and now you know exactly what to expect, what to ask, and what to do if they are not.
